Home  >  Products  >  AGPAT2 (1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase, beta) ) Blocking Peptide (the C terminal of AGPAT2)(100ug)
AGPAT2 (1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase, beta) ) Blocking Peptide (the C terminal of AGPAT2)(100ug)

AGPAT2 (1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase, beta) ) Blocking Peptide (the C terminal of AGPAT2)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-AGPAT2 Antibody (ARP44636_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP44636
Size: 100ug
Weight: 31kDa
Gene: The peptide is characterized by mass spectroscopy
Format: Lyophilized powder
Target: AGPAT2 is a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. The protein is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in its gene have been associated with congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance.
Alternative names: 1-AGPAT2; BSCL; BSCL1; LPAAB; LPAAT-beta
See Full Product Listings >